Albany, NY -- (SBWire) -- 01/23/2020 --Androstenedione Market Introduction

Androstenedione is a 19-carbon steroid hormone produced in the adrenal glands. It is known to stimulate the development of sex organs, sexual characters, and favor the development of masculine characteristics. It also shows significant effects on scalp and body hair in humans. It is considered to be a male sex hormone; however, it is present in the blood of both men and women and is a precursor that can be converted by the body into more potent androgens, such as testosterone, or converted into the female hormone estrogen.

Report Overview @ https://www.transparencymarketresearch.com/androstenedione-market.html

Androstenedione hormone secretion is controlled by two key parts of the brain (the hypothalamus and pituitary gland) which are known to control androstenedione secretion from the testes, ovaries, and adrenal cortex. Overproduction of androstenedione could lead to an imbalance in estrogen and testosterone production, leading to changes such as breast development in men and hirsutism, amenorrhoea, worsening acne, and changes to the genitalia in women.

Androstenedione Market- Competitive Landscape

Leading market players are focusing on further innovative developments of androstenedione new formulation to overcome existing limits and enhance the efficiency such as Mattern is developing MetP's Androstenedione Nasal Gel that is fast absorbed without first-pass hepatic and intestinal metabolism and therefore can be applied in much lower and safer doses.

Get a Glimpse of the In-Depth Analysis through our Comprehensive "Androstenedione Market" Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=68678

Mylan N.V.

Founded in 1849, Mylan N.V. is headquartered in New York, U.S. The company is a pharmaceutical company offering generic and branded medications. It is a leader in the U.S. generics industry. Approximately one in every 14 prescriptions dispensed in the U.S. is a Mylan product. Mylan N.V. offers more than 7,500 marketed generic and branded generic products as well as OTC products. The company operates 12 injectables facilities, eight of which are based in India. Mylan N.V. operates in more than 165 countries. North America contributes significantly to the company's revenue. The company enjoys significant presence in the U.S., Australia, and France.

Pfizer, Inc.

Founded in 1849, Pfizer, Inc. is headquartered in New York, U.S. The is a global pharmaceutical company that develops, manufactures, and markets prescription medicines in 11 therapeutic segments including cardiovascular, oncology, neuroscience, pain, and infectious diseases. The company offers a range of medicines and vaccines as well as consumer health care products for the prevention and treatment of infectious and chronic diseases for all age groups. It operates through two business units: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The company has more than 95 products in different stages of pipeline studies for disease indications, such as metabolic risks and cardiovascular risks, oncology, inflammation and immunology, neuroscience, and rare diseases.

AbbVie, Inc

Founded in 2013, AbbVie, Inc. is headquartered in Illinois, the U.S. The company is a research-oriented, global biopharmaceutical company that engages in the development and marketing of advanced therapies for highly complex and serious diseases. The company is having promising pipeline of new medicines, in the clinical development stage across fields, such as, virology/liver diseases (including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), immunology, oncology, neurological diseases, dermatology, and women's health.

Pre Book "Androstenedione Market" Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=68678

Teva Pharmaceutical Industries Ltd.

Founded in 1944, Teva Pharmaceutical Industries Ltd. is headquartered in Petah Tikva, Israel. The company is a key producer of generic medicines and a recognized leader in innovative and specialty pharmaceuticals worldwide. It is a leading generic drug company in the U.S. and Europe. The company delivers high-quality and patient-centric health care solutions across the globe. It has a wide portfolio of generic drugs with more than 1,000 molecules in almost every therapeutic area. The company primarily operates through two business segments: generic medicines and specialty medicines.

Androstenedione Market – Dynamics

Consumer Preference Increasing for Androstenedione Product

Consumer preference for androstenedione based products is expected to significantly increase over the forecast period. Manufacturers of androstenedione products are focusing on product development and optimization of products according to consumer demand. Growth in the market is increasing by factor such as increase testosterone levels, Heighten sexual arousal and function, enhance recovery and growth from exercise. Growing fitness interest among young people is paving way for androstenedione products. To achieve stringent fitness targets, sports persons and fitness enthusiasts consume androstenedione products.

In 2017, In the U.S., fertility control rate decreased by 16%, thereby augmenting the growth of androstenedione market.

Development of new formulations to offer new market leads

Localized drug delivery techniques for treatment such as the usage of creams that show better efficacy and performance are likely to be frequently sought after by medical professionals and facilities who have been dogged by severe shortcomings of current drugs. Successful observations of combination therapy have been encouraging and market leaders need to focus on combination molecules in order to gain a significant advantage due to several benefits such as lower drug doses and reduced incidence of adverse effects.